Treating Onychomychosis
Phase 2
- Conditions
- Onychomycosis
- Registration Number
- NCT00776464
- Lead Sponsor
- Nomir Medical Technologies
- Brief Summary
A study to treat 4 toes at a time to eliminate Onychomycosis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- 18 years or older
- positive onychomycosis
- negative pregnancy
Exclusion Criteria
- peripheral neuropathy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Complete or near complete disappearance of toenail fungus 360 days
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular targets are involved in Nomir's onychomycosis treatment mechanism for four-toe therapy?
How does Nomir's intervention compare to oral antifungals like terbinafine in Phase 2 onychomycosis trials?
Which biomarkers correlate with treatment response in NCT00776464's onychomycosis clinical trial?
What adverse events were reported in Nomir's Phase 2 onychomycosis trial and how were they managed?
Are there combination therapies involving Nomir's treatment and standard antifungal agents for onychomycosis?
Trial Locations
- Locations (1)
Nomir Medical
🇺🇸Waltham, Massachusetts, United States
Nomir Medical🇺🇸Waltham, Massachusetts, United StatesAlan robbins, MDContact781-893-1000alanrobbins@comcast.com